Institute of Neurology, Medical University of Vienna, Vienna, Austria
Anna Sophie Berghoff , Barbara Kiesel , Georg Widhalm , Orsolya Rajky , Gerda Ricken , Karin Dieckmann , Peter Birner , Rupert Bartsch , Christoph Zielinski , Christoph Hoeller , Johannes A. Hainfellner , Matthias Preusser
Background: The brain is considered as an immuno-privileged organ and little is known about the inflammatory response to melanoma BM. Methods: Patients with neurosurgical resected and histologically verified melanoma BM were identified. Investigation of PD1, PD-L1, CD3, CD8, CD45RO and BRAF V600E were performed by immunohistochemistry and analyzed using previously published semiquantitative evaluation criteria. Results: Forty-six specimens (28/46; 60.9% BRAF V600E positive) were available. Forty-one/46 (89.1%) specimens presented with TIL infiltration. CD3+ TILs were evident in 35/46 (76.1%), CD8+ TILs in 28/46 (60.9%), CD45RO+ TILs in 32/46 (69.6%) and PD1+ TILs in 28/46 (60.9%) specimens. The Table lists details of TIL infiltration density. PD-L1 expression on melanoma BM tumor cells was observed in 21/46 (45.7%) specimens. Median H-score for PD-L1 was 3 (range 1–90). Eight/21 (38.1%) PD-L1 positive specimens presented with an H score over 5 %. PD-L1 expression on tumor cells was associated with higher density of PD1+ (p=0.002), CD3+ (p=0.024) and CD8+ (p=0.050) TIL infiltration. Furthermore, density of CD3+ TILs was associated with density of CD8+ (p<0.001), PD1+ (p<0.001) and CD45RO+ (p<0.001) TILs, respectively. No association of previous systemic antineoplastic therapy (including chemotherapy and interferon) and expression of PD-L1, PD1, CD3 or CD45RO could be observed (p=n.s). Expression of PD-L1 on tumor cells or density of PD1+, CD3+, CD8+ or CD45RO+ TILs did not correlate with BRAF V600E status (p=n.s.) or survival from first diagnosis of BM (p=n.s.). Conclusions: Melanoma BM show considerable inflammatory infiltrates and expression of PD1 and PD-L1. Clinical studies should investigate the value of checkpoint inhibitors in patients with melanoma brain metastases.
CD3+ TILs | CD8+ TILs | CD45RO+ TILs | PD1+ TILs | |
---|---|---|---|---|
Sparse infiltration | 11/46 (23.9%) | 13/46 (28.3%) | 12/46 (26.1%) | 13/46 (38.3%) |
Moderate infiltration | 12/46 (26.1%) | 12/46 (26.1%) | 11/46 (23.9%) | 11/46 (23.9%) |
Dense infiltration | 8/46 (17.4%) | 11/46 (23.9%) | 7/46 (15.2%) | 4/46 (8.7%) |
Very dense infiltration | 4/46 (8.7%) | 5/46 (10.9%) | 2/46 (4.3%) | 0/46 (0.0%) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Anastasia O. Sitkovskaya
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Samuel Louis Cytryn
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Hidekazu Hirano
2017 ASCO Annual Meeting
First Author: Dennis O'Malley